Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Harmony Biosciences Holdings (HRMY) Gross Margin (2020 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed Gross Margin for 6 consecutive years, with 71.88% as the latest value for Q4 2025.

  • Quarterly Gross Margin fell 108.0% to 71.88% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 77.16% through Dec 2025, down 90.0% year-over-year, with the annual reading at 77.16% for FY2025, 90.0% down from the prior year.
  • Gross Margin hit 71.88% in Q4 2025 for Harmony Biosciences Holdings, down from 75.09% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 82.81% in Q2 2021 to a low of 71.88% in Q4 2025.
  • Historically, Gross Margin has averaged 79.73% across 5 years, with a median of 81.17% in 2023.
  • Biggest five-year swings in Gross Margin: tumbled -467bps in 2023 and later soared 46bps in 2025.
  • Year by year, Gross Margin stood at 80.47% in 2021, then decreased by -2bps to 79.05% in 2022, then dropped by -6bps to 74.38% in 2023, then decreased by -2bps to 72.97% in 2024, then dropped by -1bps to 71.88% in 2025.
  • Business Quant data shows Gross Margin for HRMY at 71.88% in Q4 2025, 75.09% in Q3 2025, and 80.97% in Q2 2025.